CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
High ImpactOriginal article

FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial

RegulatoryrejectedRGX-121Negative
AI Analysis

Summary

REGENXBIO announced that the FDA has placed a clinical hold on RGX-121, its investigational gene therapy for MPS II, halting further development of the program.

Clinical Trial Data

Outcome Details

FDA placed clinical hold on RGX-121

Importance:8/10
Sentiment:
-0.95
gene therapyclinical holdFDAMPS IIregulatory setback
Related Companies

Read the original article

Published by Clinical Trials Arena on August 25, 2026 9:21 AM

Read Original